Benitec Biopharma Inc.: reports FDA feedback after Type C meeting

What happened

• The filing says that on Oct 5, 2026 Benitec Biopharma Inc. issued a press release providing an update following the receipt of formal feedback from the U.S. Food and Drug Administration (FDA) related to the Type C meeting between the company and the FDA in the third quarter of the 2026 calendar year.
• The press release is attached to the 8-K as Exhibit 99.1 and the report was signed by Dr. Jerel A. Banks, chief executive officer, on Oct 5, 2026.

Key details

• Date of press release and filing: Oct 5, 2026.
• Topic: formal feedback from the FDA following a Type C meeting in the third quarter of the 2026 calendar year.
• Exhibit included: press release furnished as Exhibit 99.1.

Why it may matter

• The filing reports Item 7.01 (Regulation FD disclosure), which covers public disclosure of information the company furnished in a press release, and Item 9.01 (exhibits) listing the attached materials.
• This filing does not show why the insider traded or why the company acted.